Ernexa Therapeutics Stock (NASDAQ:ERNA)

Ownership Financials Chart

Previous Close

$6.34

52W Range

$3.18 - $71.50

50D Avg

$7.27

200D Avg

$21.53

Market Cap

$2.06M

Avg Vol (3M)

$1.62M

Beta

2.50

Div Yield

ERNA Company Profile

Ernexa Therapeutics Inc. is a biotechnology firm currently in its preclinical development phase, specializing in the creation of therapeutic interventions using induced mesenchymal stem cells (iMSCs). The company's primary focus lies in addressing solid tumor cancers and a range of autoimmune diseases. Its flagship candidate, ERNA-101, is an allogeneic iMSC designed to release pro-inflammatory cytokines, namely IL-7 and IL-15, intended for the treatment of ovarian cancer. Additionally, Ernexa is developing ERNA-102, an iMSC product engineered to secrete the anti-inflammatory cytokine IL-10, aimed at managing rheumatoid arthritis. The company has a licensing arrangement in place with Factor Bioscience Limited. Established in 2018, this Cambridge, Massachusetts-based entity operated as Eterna Therapeutics Inc. until its rebranding to Ernexa Therapeutics in March 2025.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Aug 29, 1991

Website

ERNA Performance

ERNA Financial Summary

	Dec 25	Dec 24	Dec 23
Revenue	-	$582.00K	$68.00K
Operating Income	$-9.32M	$-15.67M	$-21.14M
Net Income	$-14.10M	$-44.54M	$-21.67M
EBITDA	$-9.32M	$-36.12M	$-19.93M
Basic EPS	$-2.24	$-1.57	$-4.08
Diluted EPS	$-2.24	$-1.57	$-4.08

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

Ticker	Company
OSRH	OSR Holdings, Inc.
LNAI	Lunai Bioworks Inc.
MPLT	MapLight Therapeutics, Inc.
MBRX	Moleculin Biotech, Inc.
ADAP	Adaptimmune Therapeutics plc
DWTX	Dogwood Therapeutics, Inc.
AEMD	Aethlon Medical, Inc.
PMN	ProMIS Neurosciences, Inc.